<DOC>
	<DOCNO>NCT00444873</DOCNO>
	<brief_summary>A multicentre , prospective , open label study acromegalic patient evaluate efficacy safety different dose-intervals Lanreotide Autogel 120mg accord international standard compare previous treatment Octreotide LAR 10 , 20 30 mg .</brief_summary>
	<brief_title>Effect 120mg Somatuline Autogel Different Dose Intervals ( 28 , 42 56 Days ) Patients With Acromegaly</brief_title>
	<detailed_description>Six repeat application Lanreotide Autogel 120mg administer every 28 , 42 56 day . For first three injection , interval depend Octreotide LAR dosage administer previously . The dose interval titrate injection 3 depend efficacy therapy Lanreotide Autogel</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>The patient must give write ( personally sign date ) inform consent complete studyrelated procedure . The patient must document diagnosis active acromegaly adequately treat stable dose ( 10 , 20 30 mg ) Octreotide LAR least 6 month immediately prior study entry . A documented diagnosis active acromegaly define IGF1 30 % high two Standard Deviations ( +2 SD ) normal age sex adjust value ( see Appendix 6 ) GH level OGTT ( Oral Glucose Tolerance Test ) &gt; 2ng/mL drug treatment acromegaly . For patient undergone surgery radiotherapy , diagnosis must perform recent surgical radiation treatment The patient pituitary surgery ( adenomectomy ) within 6 month prior study entry The patient receive stereotactic ( LINAC , Gamma Knife ) radiotherapy acromegaly within three year conventional radiotherapy acromegaly within five year prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Inappropriate Growth Hormone Secretion Syndrome ( Acromegaly )</keyword>
</DOC>